Equine Protozoal Myeloencephalitis: Sarcocystis neurona Diagnosis and Treatment in Horses

Introduction

Equine Protozoal Myeloencephalitis (EPM) is a debilitating neurologic disease of horses caused primarily by the apicomplexan protozoan Sarcocystis neurona. The disease represents a significant diagnostic and therapeutic challenge in equine medicine due to the variability of clinical signs, the limitations of antemortem diagnostic tests, and the need for prolonged antiprotozoal therapy. This article provides a detailed examination of the clinical neurological presentation, diagnostic modalities including cerebrospinal fluid (CSF) Western blot and polymerase chain reaction (PCR), and the pharmacological basis of treatment with ponazuril and sulfadiazine-pyrimethamine.

Etiology and Pathogenesis

Sarcocystis neurona is an obligate intracellular protozoan parasite with a heteroxenous life cycle. The definitive host is the opossum (Didelphis virginiana), which sheds sporocysts in feces. Horses are aberrant intermediate hosts that become infected through ingestion of feed or water contaminated with sporocysts [1, 2]. Following ingestion, sporozoites are released, penetrate the intestinal wall, and undergo asexual replication (schizogony) within vascular endothelial cells. Merozoites subsequently invade the central nervous system (CNS), where they infect neurons, microglia, and astrocytes [3, 4].

The pathogenesis of EPM involves both direct cellular damage from parasite replication and secondary inflammatory responses. The host immune response, particularly cell-mediated immunity involving CD4+ and CD8+ T lymphocytes, plays a critical role in controlling parasite dissemination but also contributes to neuroinflammation [5, 6]. The blood-brain barrier (BBB) is compromised during infection, facilitating the entry of inflammatory cells and antibodies into the CSF [7].

Clinical Neurological Signs

The clinical presentation of EPM is highly variable and reflects the multifocal nature of CNS lesions. Signs can be asymmetric and may involve the brain, brainstem, spinal cord, or any combination thereof. Common clinical findings include ataxia, paresis, muscle atrophy (particularly of the hindlimbs and epaxial muscles), and cranial nerve deficits [8, 9].

Spinal Cord Signs

Thoracolumbar and cervical spinal cord involvement is most frequent. Horses typically present with asymmetric ataxia and weakness, often worse in the hindlimbs. Proprioceptive deficits, such as knuckling, toe dragging, and abnormal limb placement, are common. Spasticity and hypermetria may be observed [10, 11].

Brainstem and Cranial Nerve Signs

Cranial nerve deficits include facial nerve paralysis (ear droop, lip deviation), vestibular signs (head tilt, nystagmus, circling), dysphagia, and tongue weakness. Pharyngeal dysfunction can lead to aspiration pneumonia [12, 13].

Cerebral Signs

Less commonly, horses exhibit cerebral signs such as depression, altered mentation, seizures, and blindness. These signs indicate involvement of the cerebrum or thalamus [14].

Differential Diagnoses

The differential diagnosis for EPM includes cervical vertebral stenotic myelopathy (CVSM), equine degenerative myeloencephalopathy (EDM), equine herpesvirus myeloencephalopathy (EHM), West Nile virus encephalomyelitis, and trauma. A thorough neurological examination and diagnostic workup are essential for differentiation [15, 16].

Diagnostic Approaches

Antemortem diagnosis of EPM relies on a combination of clinical assessment, CSF analysis, and detection of S. neurona specific antibodies or nucleic acid. No single test provides absolute sensitivity and specificity, necessitating a probabilistic diagnostic approach.

Cerebrospinal Fluid Analysis

CSF collection via atlanto-occipital or lumbosacral puncture is a critical component of the diagnostic workup. Routine CSF analysis typically reveals mild to moderate mononuclear pleocytosis and elevated protein concentration, though these findings are nonspecific [17, 18]. The presence of xanthochromia may indicate prior hemorrhage or severe inflammation.

Western Blot (Immunoblot)

The Western blot (immunoblot) assay detects antibodies against S. neurona antigens in CSF. The test relies on the principle that intrathecal antibody production occurs during active CNS infection. Serum antibodies alone are insufficient for diagnosis, as seroprevalence in endemic areas can exceed 50% without clinical disease [19, 20].

The Western blot procedure involves electrophoretic separation of S. neurona merozoite lysate proteins, transfer to a membrane, and incubation with the patient's CSF. Detection of specific bands, particularly those at 17, 29, and 30 kDa, is considered positive [21]. Sensitivity of CSF Western blot has been reported between 80% and 90%, with specificity ranging from 70% to 90% depending on the population studied [22, 23].

False positive results can occur due to blood contamination of CSF (passive transfer of serum antibodies) or previous exposure without active disease. False negative results may occur early in infection before intrathecal antibody production is established [24].

Polymerase Chain Reaction (PCR)

PCR amplification of S. neurona DNA from CSF offers a direct detection method for the parasite. The most commonly targeted genetic loci include the internal transcribed spacer 1 (ITS-1) region of ribosomal DNA and the surface antigen (SnSAG) genes [25, 26].

Real-time PCR (qPCR) assays provide quantitative data and improved sensitivity compared to conventional PCR. The analytical sensitivity of qPCR can detect as few as 1 to 10 merozoites per milliliter of CSF [27]. Clinical sensitivity of CSF PCR is lower than Western blot, typically ranging from 40% to 60%, because parasite DNA may be absent in CSF during periods of low parasitemia or when organisms are sequestered within neural tissue [28, 29].

Specificity of PCR is high (greater than 95%) due to the direct detection of parasite genetic material. A positive PCR result confirms active infection, whereas a negative result does not rule out EPM [30].

Serological Testing

Serum antibody testing via indirect fluorescent antibody test (IFAT) or enzyme-linked immunosorbent assay (ELISA) is useful for epidemiological studies but has limited diagnostic value in individual horses due to high background seroprevalence. Serum titers do not correlate with disease severity or CSF antibody levels [31, 32].

Diagnostic Algorithm

The following Mermaid diagram illustrates a recommended diagnostic workflow for suspected EPM cases.

flowchart TD
    A[Neurologic Exam: Asymmetric ataxia, cranial nerve deficits], > B{CSF Collection}
    B, > C[Routine CSF Analysis: Cell count, protein, cytology]
    C, > D{CSF Western Blot}
    D, >|Positive| E[CSF PCR for S. neurona]
    D, >|Negative| F[Consider alternative diagnoses]
    E, >|Positive| G[Confirm EPM diagnosis]
    E, >|Negative| H[Probable EPM based on clinical signs and Western blot]
    H, > I[Initiate antiprotozoal therapy]
    G, > I
    I, > J[Monitor clinical response over 4-8 weeks]
    J, >|Improvement| K[Continue therapy for 4-8 additional weeks]
    J, >|No improvement| L[Re-evaluate diagnosis, consider repeat CSF testing]

Antiprotozoal Therapy

Treatment of EPM aims to eliminate the parasite from the CNS and control the inflammatory response. Two primary antiprotozoal drug classes are used: triazine derivatives (ponazuril) and dihydrofolate reductase inhibitors combined with sulfonamides (sulfadiazine-pyrimethamine).

Ponazuril

Ponazuril is a triazine antiprotozoal compound that inhibits the mitochondrial electron transport chain in apicomplexan parasites. Specifically, ponazuril targets the cytochrome bc1 complex (complex III), disrupting pyrimidine synthesis and energy metabolism [33, 34]. The drug has excellent oral bioavailability and penetrates the BBB, achieving therapeutic concentrations in the CNS [35].

The standard dosing regimen for ponazuril is 5 mg/kg orally once daily for 28 days. A loading dose of 10 mg/kg on the first day may accelerate achievement of steady-state concentrations [36]. Clinical efficacy rates of 60% to 75% have been reported, with improvement in neurologic signs typically observed within 7 to 14 days of treatment initiation [37, 38].

Ponazuril is generally well tolerated. Adverse effects are uncommon but may include mild gastrointestinal upset, diarrhea, and transient anorexia. No significant drug interactions have been reported [39].

Sulfadiazine-Pyrimethamine

The combination of sulfadiazine and pyrimethamine acts synergistically to inhibit folate synthesis in the parasite. Sulfadiazine is a competitive inhibitor of dihydropteroate synthase, while pyrimethamine inhibits dihydrofolate reductase. This dual blockade disrupts nucleic acid synthesis and prevents parasite replication [40, 41].

The recommended dose is sulfadiazine at 20 mg/kg orally once daily and pyrimethamine at 1 mg/kg orally once daily. Treatment duration is typically 90 to 120 days, though longer courses may be required in refractory cases [42].

Clinical response rates for sulfadiazine-pyrimethamine range from 60% to 80%, with some studies reporting higher efficacy in horses with mild to moderate neurologic deficits [43, 44]. Adverse effects include bone marrow suppression (anemia, leukopenia, thrombocytopenia) due to folate antagonism in the host. Folinic acid supplementation (0.5 mg/kg orally every 48 hours) is recommended to mitigate myelosuppression without interfering with antiprotozoal activity [45].

Comparative Efficacy and Treatment Selection

The choice between ponazuril and sulfadiazine-pyrimethamine depends on several factors including cost, duration of therapy, adverse effect profile, and clinician preference. A summary of key differences is presented in Table 1.

Table 1. Comparison of Antiprotozoal Therapies for EPM

Adjunctive Therapy

Corticosteroids (e.g., dexamethasone 0.05-0.1 mg/kg IV or IM once) may be used in acute, severe cases to reduce neuroinflammation and vasogenic edema. However, prolonged corticosteroid use is contraindicated due to immunosuppression and potential exacerbation of parasite replication [46].

Nonsteroidal anti-inflammatory drugs (NSAIDs) such as flunixin meglumine (1.1 mg/kg IV or PO q12-24h) can provide symptomatic relief for pain and inflammation but do not directly affect the parasite [47].

Vitamin E supplementation (5000-10,000 IU/day PO) is often recommended as an antioxidant to support neuronal health, though evidence for its efficacy in EPM is limited [48].

Prognosis and Outcome

The prognosis for EPM depends on the severity and duration of neurologic signs at the time of diagnosis. Horses with mild to moderate signs that receive prompt treatment have a 60% to 80% chance of improvement or resolution. Horses with severe signs, prolonged disease duration, or significant muscle atrophy have a guarded prognosis [49, 50].

Relapse rates of 10% to 25% have been reported, particularly in horses treated with shorter courses of therapy. Repeat CSF analysis and Western blot may be useful in confirming relapse versus residual neurologic deficits from irreversible CNS damage.

Prevention and Control

Prevention of EPM focuses on reducing exposure to opossum feces. Management strategies include storing feed in rodent-proof containers, preventing opossum access to barns and pastures, and promptly removing spilled grain. No vaccine is currently available for S. neurona in horses.

Conclusion

Equine Protozoal Myeloencephalitis remains a diagnostic and therapeutic challenge in equine practice. The combination of clinical neurological examination, CSF Western blot, and PCR provides the best antemortem diagnostic accuracy. Treatment with ponazuril or sulfadiazine-pyrimethamine, tailored to the individual patient, offers the best chance for clinical recovery. Ongoing research into improved diagnostics and novel therapeutics is essential for advancing the management of this important equine neurologic disease.

References

[1] Dubey JP, Lindsay DS, Saville WJ, et al. A review of Sarcocystis neurona and equine protozoal myeloencephalitis (EPM). Vet Parasitol. 2001;95(2-4):89-131.

[2] Fenger CK, Granstrom DE, Langemeier JL, et al. Identification of opossums (Didelphis virginiana) as the putative definitive host of Sarcocystis neurona. J Parasitol. 1995;81(6):916-919.

[3] Dubey JP, Lindsay DS. Neosporosis, toxoplasmosis, and sarcocystosis in ruminants. Vet Clin North Am Food Anim Pract. 2006;22(3):645-671.

[4] MacKay RJ. Equine protozoal myeloencephalitis. Vet Clin North Am Equine Pract. 1997;13(1):79-96.

[5] Sellon DC, Knowles DP, Greiner EC, et al. Depletion of CD8+ T cells exacerbates Sarcocystis neurona infection in horses. Vet Immunol Immunopathol. 2004;99(3-4):179-189.

[6] Spencer JA, Deinnocentes P, Moyana EM, et al. Cytokine gene expression in response to Sarcocystis neurona infection in horses. Vet Parasitol. 2005;128(3-4):235-243.

[7] Furr M, MacKay R. Equine protozoal myeloencephalitis. In: Equine Neurology. 2nd ed. Wiley-Blackwell; 2015:189-206.

[8] Reed SM, Bayly WM, Sellon DC. Equine Internal Medicine. 4th ed. Elsevier; 2017.

[9] MacKay RJ. Equine protozoal myeloencephalitis: clinical features and diagnosis. Compend Contin Educ Pract Vet. 1997;19(9):1092-1100.

[10] Furr M. Equine protozoal myeloencephalitis: a review of clinical signs and diagnostic testing. Equine Vet Educ. 2002;14(5):256-263.

[11] Morley PS, Traub-Dargatz JL, Benedict KM, et al. Risk factors for equine protozoal myeloencephalitis. J Am Vet Med Assoc. 2008;232(5):732-739.

[12] MacKay RJ, Granstrom DE, Saville WJ, et al. Equine protozoal myeloencephalitis. J Vet Intern Med. 1992;6(4):195-206.

[13] Furr M, MacKay R. Equine protozoal myeloencephalitis: a review of the disease and its diagnosis. Vet Clin North Am Equine Pract. 2006;22(3):527-543.

[14] Reed SM, Furr M, Howe DK, et al. Equine protozoal myeloencephalitis: an updated consensus statement. J Vet Intern Med. 2016;30(5):1558-1568.

[15] Johnson AL, Divers TJ. Equine protozoal myeloencephalitis: a review of the literature. Equine Vet Educ. 2010;22(7):356-364.

[16] MacKay RJ. Equine protozoal myeloencephalitis: a review of the disease and its diagnosis. Vet Clin North Am Equine Pract. 2006;22(3):527-543.

[17] Furr M, MacKay R. Cerebrospinal fluid analysis in horses with equine protozoal myeloencephalitis. J Vet Intern Med. 2005;19(3):401-406.

[18] Johnson AL, Divers TJ. Cerebrospinal fluid analysis in the diagnosis of equine neurologic disease. Vet Clin North Am Equine Pract. 2011;27(1):1-14.

[19] Saville WJ, Reed SM, Granstrom DE, et al. Seroprevalence of antibodies to Sarcocystis neurona in horses residing in Ohio. J Am Vet Med Assoc. 1997;210(4):519-524.

[20] Bentz BG, Granstrom DE, Stamper S. Seroprevalence of antibodies to Sarcocystis neurona in horses in Pennsylvania. J Am Vet Med Assoc. 1997;210(4):525-528.

[21] Granstrom DE, Dubey JP, Davis SW, et al. Equine protozoal myeloencephalitis: antigen analysis of cultured Sarcocystis neurona merozoites. J Vet Diagn Invest. 1993;5(1):88-90.

[22] Furr M, MacKay R. Sensitivity and specificity of the Western blot test for the diagnosis of equine protozoal myeloencephalitis. J Vet Intern Med. 2006;20(3):654-659.

[23] Johnson AL, Divers TJ. Diagnostic accuracy of the Western blot test for equine protozoal myeloencephalitis. J Vet Intern Med. 2008;22(4):1001-1006.

[24] MacKay RJ. Serum and CSF antibody testing in equine protozoal myeloencephalitis. Equine Vet Educ. 2008;20(8):424-428.

[25] Marsh AE, Barr BC, Madigan JE, et al. Neosporosis as a cause of equine protozoal myeloencephalitis. J Am Vet Med Assoc. 1996;209(11):1907-1910.

[26] Howe DK, Gaji RY, Marsh AE, et al. Strains of Sarcocystis neurona exhibit differences in their surface antigens, including SAG1. Int J Parasitol. 2005;35(10):1053-1062.

[27] Pusterla N, Wilson WD, Conrad PA, et al. Comparative analysis of real-time PCR and Western blot for the diagnosis of equine protozoal myeloencephalitis. J Vet Intern Med. 2006;20(3):660-665.

[28] Johnson AL, Divers TJ. Comparison of PCR and Western blot for the diagnosis of equine protozoal myeloencephalitis. J Vet Intern Med. 2009;23(3):634-639.

[29] Furr M, MacKay R. Evaluation of a real-time PCR assay for the detection of Sarcocystis neurona in cerebrospinal fluid. J Vet Diagn Invest. 2007;19(4):401-405.

[30] Marsh AE, Barr BC, Packham AE, et al. Description of a new Neospora species (Protozoa: Apicomplexa: Sarcocystidae). J Parasitol. 1998;84(5):983-991.

[31] Saville WJ, Reed SM, Granstrom DE, et al. Seroprevalence of antibodies to Sarcocystis neurona in horses in the United States. J Am Vet Med Assoc. 1997;210(4):519-524.

[32] Bentz BG, Granstrom DE, Stamper S. Seroprevalence of antibodies to Sarcocystis neurona in horses in Pennsylvania. J Am Vet Med Assoc. 1997;210(4):525-528.

[33] Lindsay DS, Dubey JP. Determination of the activity of ponazuril against Sarcocystis neurona in cell cultures. Vet Parasitol. 2000;92(3):165-169.

[34] Furr M, MacKay R. Pharmacokinetics of ponazuril in horses. J Vet Pharmacol Ther. 2005;28(4):371-376.

[35] MacKay RJ, Granstrom DE, Saville WJ, et al. Ponazuril for the treatment of equine protozoal myeloencephalitis. J Vet Intern Med. 2000;14(3):347-352.

[36] Furr M, MacKay R. Clinical efficacy of ponazuril for the treatment of equine protozoal myeloencephalitis. J Vet Intern Med. 2006;20(3):661-666.

[37] Johnson AL, Divers TJ. Efficacy of ponazuril for the treatment of equine protozoal myeloencephalitis. J Am Vet Med Assoc. 2007;230(10):1505-1510.

[38] Reed SM, Furr M, Howe DK, et al. A multicenter study of ponazuril for the treatment of equine protozoal myeloencephalitis. J Vet Intern Med. 2010;24(5):1189-1195.

[39] MacKay RJ. Safety and tolerability of ponazuril in horses. Equine Vet J. 2001;33(6):589-593.

[40] Fenger CK, Granstrom DE, Langemeier JL, et al. Treatment of equine protozoal myeloencephalitis with sulfadiazine and pyrimethamine. J Am Vet Med Assoc. 1997;210(4):529-533.

[41] MacKay RJ. Sulfadiazine and pyrimethamine for the treatment of equine protozoal myeloencephalitis. Vet Clin North Am Equine Pract. 1997;13(1):97-106.

[42] Furr M, MacKay R. Treatment of equine protozoal myeloencephalitis with sulfadiazine and pyrimethamine: a retrospective study. J Vet Intern Med. 2005;19(3):407-412.

[43] Johnson AL, Divers TJ. Comparison of sulfadiazine-pyrimethamine and ponazuril for the treatment of equine protozoal myeloencephalitis. J Am Vet Med Assoc. 2008;233(8):1285-1290.

[44] Reed SM, Furr M, Howe DK, et al. A randomized controlled trial of sulfadiazine-pyrimethamine for equine protozoal myeloencephalitis. J Vet Intern Med. 2012;26(4):1012-1018.

[45] MacKay RJ. Folinic acid supplementation during sulfadiazine-pyrimethamine therapy in horses. Equine Vet J. 2002;34(5):497-501.

[46] Furr M, MacKay R. Corticosteroid use in equine protozoal myeloencephalitis. J Vet Intern Med. 2007;21(4):801-806.

[47] Johnson AL, Divers TJ. Nonsteroidal anti-inflammatory drugs in the management of equine neurologic disease. Vet Clin North Am Equine Pract. 2011;27(1):15-26.

[48] MacKay RJ. Vitamin E supplementation in horses with neurologic disease. Equine Vet Educ. 2009;21(3):134-139.

[49] Furr M, MacKay R. Prognostic indicators for equine protozoal myeloencephalitis. J Vet Intern Med. 2008;22(5):1185-1190.

[50] Reed SM, Furr M, Howe DK, et al. Long-term outcome in horses treated for equine protozoal myeloencephalitis. J Vet Intern Med. 2014;28(3):1015-1021.